Caris Life Sciences, Inc. (CAI)
NASDAQ: CAI · Real-Time Price · USD
36.12
-0.44 (-1.20%)
Sep 3, 2025, 10:59 AM - Market open

Caris Life Sciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22
533.85412.26306.13258.49
Revenue Growth (YoY)
106.53%34.67%18.43%-
Cost of Revenue
246.34231.83214.87178.46
Gross Profit
287.51180.4391.2680.02
Selling, General & Admin
360.89326.05296.04294.51
Research & Development
100.45111.5114.77101.27
Operating Expenses
461.34437.55410.81395.78
Operating Income
-173.83-257.12-319.55-315.76
Interest Expense
-59.05-50.03-31.61-26.68
Interest & Investment Income
4.847.1211.260.95
Other Non Operating Income (Expenses)
-33.0718.149.420.66
EBT Excluding Unusual Items
-261.12-281.89-330.5-320.83
Other Unusual Items
-17.93--10.92-
Pretax Income
-279.05-281.89-341.42-320.83
Net Income
-279.05-281.89-341.42-320.83
Preferred Dividends & Other Adjustments
519.5396.37121.1179
Net Income to Common
-798.58-378.26-462.53-399.83
Shares Outstanding (Basic)
43353533
Shares Outstanding (Diluted)
43353533
Shares Change (YoY)
28.88%1.59%4.73%-
EPS (Basic)
-18.57-10.66-13.24-11.98
EPS (Diluted)
-18.57-10.66-13.24-11.98
Free Cash Flow
-140.59-253.64-298.42-327.96
Free Cash Flow Per Share
-3.27-7.15-8.54-9.83
Gross Margin
53.86%43.77%29.81%30.96%
Operating Margin
-32.56%-62.37%-104.38%-122.16%
Profit Margin
-149.59%-91.75%-151.09%-154.68%
Free Cash Flow Margin
-26.33%-61.52%-97.48%-126.88%
EBITDA
-140.78-208.21-270.55-267.5
EBITDA Margin
-26.37%-50.50%-88.38%-103.49%
D&A For EBITDA
33.0548.914948.25
EBIT
-173.83-257.12-319.55-315.76
EBIT Margin
-32.56%-62.37%-104.38%-122.16%
Revenue as Reported
533.85412.26306.13258.49
Advertising Expenses
-1.20.61
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q